Rapid acceleration of diagnostics (radx) program: tech project # 6808: saliva-based sars-COV-2 rapid diagnostic test
Ended Definitive Contract Awarded Last action
- Contract number
- 75N92021C00016
- Awardee
-
Salignostics LTD UEI D9HVGCXJZK81
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $890,386
Award facts
- Opportunity
-
- Rapid Acceleration of Diagnostics (RADx) Program: Tech Project # 6808: Saliva-based SARS-CoV-2 Rapid Diagnostic Test Award Notice · Posted May 18, 2021
- Contract value 100% obligated
- $890,386.49 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Biomedical Imaging and Bioenginering National Institutes of Health, Department of Health and Human Services
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Israel
- National interest action
- Coronavirus COVID-19
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Definitize Change Order | -$1,729,614 | |
| Other Administrative Action | $0 | |
| Definitize Change Order | $0 | |
| Original award | $2,620,000 |
About this award
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) awarded a $890,386.49 firm fixed-price definitive contract to Salignostics LTD for the development of a saliva-based SARS-CoV-2 rapid diagnostic test under the Rapid Acceleration of Diagnostics (RADX) Program, Tech Project #6808. The contract, awarded on May 17, 2021, with an ultimate completion date of November 8, 2021, supports the federal government's coronavirus response efforts. Performance of the work is designated to occur in Israel, and no set-aside designation was utilized for this procurement.
The RADX Program represents a coordinated federal initiative to accelerate the development and deployment of COVID-19 diagnostic technologies. This contract specifically focuses on advancing rapid testing capabilities through saliva-based diagnostics, which offer practical advantages over traditional nasopharyngeal collection methods. As a NIBIB-funded initiative under its mission to support biomedical imaging and bioengineering research, the engagement with Salignostics LTD reflects the government's strategy to leverage international expertise and innovation in diagnostic development during the pandemic response period.
Quick answers
Who was awarded contract 75N92021C00016?
75N92021C00016 was awarded to Salignostics LTD by National Heart Lung and Blood Institute (National Institutes of Health) on May 17, 2021.
How much is contract 75N92021C00016 worth?
The government has obligated $890,386 on 75N92021C00016.
Which agency awarded contract 75N92021C00016?
National Heart Lung and Blood Institute (National Institutes of Health) awarded 75N92021C00016, with funding from National Institute of Biomedical Imaging and Bioenginering (National Institutes of Health).
Was contract 75N92021C00016 competed?
The extent of competition for 75N92021C00016 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award